0.490
-0.02 (-2.99%)
| Previous Close | 0.505 |
| Open | 0.505 |
| Volume | 52,115 |
| Avg. Volume (3M) | 2,059,440 |
| Market Cap | 4,354,965 |
| Price / Earnings (Forward) | 1.43 |
| Price / Sales | 6.02 |
| Price / Book | 0.780 |
| 52 Weeks Range | |
| Earnings Date | 10 Apr 2025 |
| Profit Margin | -102.80% |
| Operating Margin (TTM) | -69.57% |
| Quarterly Revenue Growth (YOY) | 382.00% |
| Total Debt/Equity (MRQ) | 914.75% |
| Current Ratio (MRQ) | 0.540 |
| Operating Cash Flow (TTM) | -9.37 M |
| Levered Free Cash Flow (TTM) | -5.39 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -1,708.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Redhill Biopharma Ltd. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | -3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -4.0 |
| Relative Valuation | NA |
| Financial Health | -5.0 |
| AI Insight | NA |
| Weighted Average | -1.45 |
Select this tab to load the latest available analysis.
|
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Institutions | 4.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gagnon Securities Llc | 30 Jun 2026 | 88,405 |
| Lido Advisors, Llc | 30 Jun 2026 | 11,009 |
| Smartleaf Asset Management Llc | 30 Jun 2026 | 5 |
| Vermillion Wealth Management, Inc. | 30 Jun 2026 | 2 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RADAY GILEAD | - | 0.480 | -14,310,000 | -6,868,800 |
| Aggregate Net Quantity | -14,310,000 | |||
| Aggregate Net Value ($) | -6,868,800 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 0.480 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RADAY GILEAD | Officer | 01 Oct 2026 | Sell (-) | 14,310,000 | 0.480 | 6,868,800 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |